Email this article 
V. Richter: "The low toxicity and originality of the pharmaceutical agent are its major advantages"
- Authors: Richter V.A.1
- Affiliations:
- Institute of Chemical Biology and Fundamental Medicine, SB RAS
- Issue: Vol 4, No 1 (2012)
- Pages: 9-11
- Section: Forum
- URL: http://actanaturae.ru/2075-8251/article/view/10627
- DOI: https://doi.org/10.32607/20758251-2012-4-1-9-11
- Cite item
Abstract
There is no question that the government needs to provide vigorous financial support to Russian researchers looking to design new drugs. A different question is to what extent should the government participate in the financing and at
what point should industrial investors join in?
V. A. Richter
Institute of Chemical Biology and Fundamental Medicine, SB RAS
Author for correspondence.
Email: actanaturae@gmail.com
Russian Federation
- www.nanoscopy.org/bionanoscopy/actanaturae.ru
Views
Abstract - 376
PDF (English) - 126
PDF (Russian) - 134
Cited-By
Article Metrics
Metrics Loading ...
Metrics powered by PLOS ALM
